Dr. Reddy’s Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. market.
Dr. Reddy’s Laboratories Ltd. has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran* (melphalan hydrochloride) for Injection in the United States market as approved by the U.S. Food and Drug Administration.
Alkeran for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate, according to RxList.
The Alkeran brand and generic had U.S. sales of approximately $107 million MAT (moving annual total) for the most recent twelve months ending in October 2017, according to IMS Health**.
Dr. Reddy’s Melphalan Hydrochloride for Injection is available in a carton containing one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.
* Alkeran® is a registered trademark of Apotex, Inc.
** IMS National Sales Perspective: Retail and Non-Retail MAT October 2017
DY-1217-189
(Source: Dr. Reddy’s Laboratories Ltd.; RxList, Inc.)
